rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2020-233-237rsp-2882Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSТяжелое течение анкилозирующего спондилита с резистентностью к медикаментозной терапииTHE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIShttps://orcid.org/0000-0002-1684-1213РумянцеваД. Г.RumyantsevaD. G.rumiantceva01@gmail.comhttps://orcid.org/0000-0003-4190-4471ПодрядноваМ. В.PodryadnovaM. V.https://orcid.org/0000-0002-7569-4110РумянцеваО. А.RumyantsevaO. A.https://orcid.org/0000-0002-9755-5760УрумоваМ. М.UrumovaM. M.https://orcid.org/0000-0003-3195-5187ЭрдесШ.ErdesSh.ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202027042020582232237Copyright © Румянцева Д.Г., Подряднова М.В., Румянцева О.А., Урумова М.М., Эрдес Ш., 20202020Румянцева Д.Г., Подряднова М.В., Румянцева О.А., Урумова М.М., Эрдес Ш.Rumyantseva D.G., Podryadnova M.V., Rumyantseva O.A., Urumova M.M., Erdes S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2882анкилозирующий спондилитгенно-инженерные биологические препаратывысокая активностьнеэффективность генно-инженерных биологических препаратовankylosing spondylitisbiological agentshigh activityinefficacy of biological agentsReferencesЭрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60. doi: 10.14412/1995-4484-2015-657-660Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60. doi: 10.14412/1995-4484-2015-657-660 (In Russ.)Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815-22. doi: 10.1136/annrheumdis-2012-201766Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815-22. doi: 10.1136/annrheumdis-2012-201766Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276-81. doi: 10.1136/ard.2007.073098Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276-81. doi: 10.1136/ard.2007.073098Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheum. 2015;67:2702-12. doi: 10.1002/art.39257Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheum. 2015;67:2702-12. doi: 10.1002/art.39257Vastesaeger N, Cruyssen BV, Mulero J, et al. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin. 2014;10:204-9. doi: 10.1016/j.reuma.2013.12.006Vastesaeger N, Cruyssen BV, Mulero J, et al. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin. 2014;10:204-9. doi: 10.1016/j.reuma.2013.12.006Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:973-81. doi: 10.1136/ard.2010.147744Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:973-81. doi: 10.1136/ard.2010.147744Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801-8. doi: 10.3899/jrheum.081048Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801-8. doi: 10.3899/jrheum.081048Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149-55. doi: 10.1136/annrheumdis-2012-201933Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149-55. doi: 10.1136/annrheumdis-2012-201933Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18(1):71. doi: 10.1186/s13075-016-0969-2Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18(1):71. doi: 10.1186/s13075-016-0969-2Polo y La Borda J, Campos J, Sanz J, et al. Predictive clinicalgenetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis. Int J Rheum Dis. 2019;22(8):1529-37. doi: 10.1111/1756-185X.13607Polo y La Borda J, Campos J, Sanz J, et al. Predictive clinicalgenetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis. Int J Rheum Dis. 2019;22(8):1529-37. doi: 10.1111/1756-185X.13607Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711-5. doi: 10.1002/art.21671Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711-5. doi: 10.1002/art.21671Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352-4. doi: 10.1038/2031352a0Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352-4. doi: 10.1038/2031352a0Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009 May;21(3):211-5. doi: 10.1097/BOR.0b013e328329ed8bWolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009 May;21(3):211-5. doi: 10.1097/BOR.0b013e328329ed8bDe Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(4):531-5. doi: 10.1136/ard.2008.089979De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(4):531-5. doi: 10.1136/ard.2008.089979Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73(6):1138-43. doi: 10.1136/annrheumdis-2013-203296Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73(6):1138-43. doi: 10.1136/annrheumdis-2013-203296Reid V, Castelino M, Parker B, et al. Harmonised Biologics Pathway for Ankylosing Spondylitis (including non-radiographic axial spondyloarthritis – AS) and Psoriatic Arthritis PsA. 2018. Available at: http://gmmmg.nhs.uk/docs/guidance/GMMMGAS-PsA-pathway-v4-2a.pdfReid V, Castelino M, Parker B, et al. Harmonised Biologics Pathway for Ankylosing Spondylitis (including non-radiographic axial spondyloarthritis – AS) and Psoriatic Arthritis PsA. 2018. Available at: http://gmmmg.nhs.uk/docs/guidance/GMMMGAS-PsA-pathway-v4-2a.pdfDucourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011 Jun 27;13(3):R105. doi: 10.1186/ar3386Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011 Jun 27;13(3):R105. doi: 10.1186/ar3386Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum. 2019;71(10):1599-613. doi: 10.1002/art.41042Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum. 2019;71(10):1599-613. doi: 10.1002/art.41042
The authors declare that there are no conflicts of interest present.